SC
CLVS

Sculptor Capital’s Clovis Oncology, Inc. CLVS Stock Holding History

Sculptor Capital’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-10,700
Closed -$112K – 322
2019
Q4 		$112K Buy
+10,700
New +$77.8K ﹤0.01% 263

Other funds holding CLVS

N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

Sculptor Capital's CLVS Position: Q1 2022 in Review

Sculptor Capital sold out of Clovis Oncology, Inc. (CLVS) in Q1 2022, closing a stake of 216,300 shares — an estimated $586K sold.

Sculptor Capital first reported a position in CLVS in Q3 2019 and held it in 9 quarters. The position peaked at $2.63M in Q1 2021. 153 funds tracked by Wall St. Rank hold CLVS as of Q1 2022.

  • Sculptor Capital reported no remaining Clovis Oncology, Inc. position as of Q1 2022 after selling out during the quarter.
  • Sculptor Capital sold 216,300 Clovis Oncology, Inc. shares in Q1 2022, an estimated $586K.
  • Sculptor Capital first reported a position in Clovis Oncology, Inc. in Q3 2019 and held it in 9 quarters.
  • Sculptor Capital's Clovis Oncology, Inc. position peaked at $2.63M in Q1 2021.
  • 153 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q1 2022.

Based on Sculptor Capital's 13F filing for Q1 2022, filed 13 May 2022.